Which statement about diuretic therapy in CHF is true?

Which statement about diuretic therapy in CHF is true?

• A. Diuretics increase preload
• B. Diuretics relieve symptoms by decreasing preload and edema
• C. Diuretics improve mortality independent of dosing
• D. Diuretics cure heart failure

Answer: (C)

Diuretics in heart failure mainly relieve congestion and symptoms. By promoting fluid loss, they reduce intravascular volume, which lowers preload. That decrease in preload helps relieve pulmonary and peripheral edema, improves dyspnea, and enhances exercise tolerance. Because of this symptom-focused effect, diuretics are essential for acute and chronic congestion management. They do not alter the underlying disease process that drives heart failure, so they do not improve long-term survival or cure the condition. Mortality benefits come from disease-modifying therapies that address neurohormonal activation and remodeling, such as ACE inhibitors or ARBs (or ARNIs), beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. Higher diuretic doses don’t prove a mortality benefit; they can reflect more severe disease and carry risks like electrolyte disturbances, dehydration, and kidney function impairment. So the true statement is that diuretics relieve symptoms by decreasing preload and edema, not by improving mortality or curing heart failure.

Diuretics in heart failure mainly relieve congestion and symptoms. By promoting fluid loss, they reduce intravascular volume, which lowers preload. That decrease in preload helps relieve pulmonary and peripheral edema, improves dyspnea, and enhances exercise tolerance. Because of this symptom-focused effect, diuretics are essential for acute and chronic congestion management.

They do not alter the underlying disease process that drives heart failure, so they do not improve long-term survival or cure the condition. Mortality benefits come from disease-modifying therapies that address neurohormonal activation and remodeling, such as ACE inhibitors or ARBs (or ARNIs), beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors.

Higher diuretic doses don’t prove a mortality benefit; they can reflect more severe disease and carry risks like electrolyte disturbances, dehydration, and kidney function impairment. So the true statement is that diuretics relieve symptoms by decreasing preload and edema, not by improving mortality or curing heart failure.